PARI Pharmaceuticals is a German aerosol therapy company. It is spinning out a Phase III effort to develop a drug/device combo targeting a rare lung condition. The program pairs an inhaled drug formulation with a delivery device. The spinout has secured $46M in financing to advance the program. The company is moving directly into Phase III clinical testing with this asset. The available article focuses on the new spinout, its $46M raise, and the plan to proceed into late‑stage trials.

Total raised

$46M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2017